Answers are grounded in this paper and cite their sources.
Massive genomic analyses have underscored the diversity of chronic lymphocytic leukaemia (CLL) between patients. Genetic heterogeneity of tumour clones within a patient may fuel tumour evolution. Several recurrently deregulated intra-cellular pathways are candidates for targeted therapies that are very promising and are dramatically changing clinical patients' perspectives. In this review we present an overview of the genetic and epigenetic features of CLL and their clinical and biological implications.
No takes yet. Share an insight, caveat, or question.
Ghamlouch et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: